Your session is about to expire
← Back to Search
ACHIEVE-3 Trial Summary
This trial will compare a new diabetes drug with semaglutide to see if it's safe and effective for people with Type 2 diabetes who take metformin. The trial will last 61 weeks.
- Type 2 Diabetes
ACHIEVE-3 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
ACHIEVE-3 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
ACHIEVE-3 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many healthcare facilities are administering this trial?
"Currently, 134 participants have enrolled in this clinical trial – these include the San Fernando Valley Health Institute of Canoga Park, Neighborhood Healthcare Institute of Escondido and Velocity Clinical Research Gardena. Additionally, there are other sites around the country."
What potential adverse effects can be caused by administering Orforglipron Dose 1?
"Orforglipron Dose 1 has been proven safe in prior clinical studies, thus it was assigned a score of 3."
Are there any remaining opportunities for individuals to partake in this research?
"The details posted on clinicaltrials.gov inform us that this study is not presently engaging in patient recruitment. It was initially featured on September 27th 2023 and last updated nine days later, but 1479 other trials are actively searching for candidates right now."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends